Elixinol Global Ltd (ELLXF)

[ANIA77]

I'm hoping to see their Sativa organic hemp skin line to hit retail chain stores soon. It could generate nice profit since there is not much competition out there yet and they have already 8 products just for skin line.

https://elixinol.com/sativaskincare/

[Itchy palm]

Looking good here GLTA

[mick]

Press Release: Elixinol Global Limited FY2018 Results Strong Revenue Growth of 121% Supported by Robust Balance Sheet to Drive Future Growth
12:33 pm ET February 27, 2019 (Dow Jones) Print
Press Release: Elixinol Global Limited FY2018 Results Strong Revenue Growth of 121% Supported by Robust Balance Sheet to Drive Future Growth

Elixinol Global Limited FY2018 Results Strong Revenue Growth of 121% Supported by Robust Balance Sheet to Drive Future Growth

SYDNEY, Australia, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Elixinol Global Limited (EXL or the Group) (ASX:EXL; OTCQX:ELLXF), a global company operating in the industrial hemp and emerging medicinal cannabis sectors, is pleased to release its FY2018 results for the financial year ending 31 December 2018.

FY2018 KEY HIGHLIGHTS:

-- Group revenue increased 121% to $37.1m1 driven by continued strong sales

by Elixinol

-- Underlying EBITDA of $0.7m in FY2018 compared to breakeven in FY20172

-- Strong balance sheet with net cash of $42.7m to drive international

growth

-- Elixinol investing to build a global presence, with significant capital

deployed into scaleup, following positive regulatory developments

-- Hemp Foods Australia invested for top line growth during FY2018 with

revenue growing to $4.9m3 , up 51% on FY2017

-- Nunyara Pharma unique 60 acre land holding purchased in Australia in

early FY2019, post year end

(1) All dollar amounts are in AUD unless otherwise stated; Average AUD/USD for Q4 FY2018 = 0.7170

(2) FY2017 is shown on a pro forma basis

(3) Includes $0.3m of intercompany sales of Sativa products (eliminated upon consolidation)

A$m (December year-end) FY2017(2) FY2018

Revenue 16.8 37.1 (up 121%)

Underlying EBITDA (0.0) 0.7

Underlying NPAT (1.9) 0.7

Statutory NPAT (2.7) (0.9)

EXL is a diverse portfolio of hemp and cannabis companies trading globally including:

-- Elixinol - hemp-derived CBD business based out of Colorado, USA

-- Hemp Foods Australia - hemp foods, raw materials and finished products

-- Nunyara Pharma "Nunyara" - emerging medicinal cannabis business

Strong revenue growth reported in FY2018

For the first full trading year since its ASX listing in January 2018, EXL is pleased to report group revenue of $37.1m for FY2018 representing substantial 121% growth over FY2017.

Underlying EBITDA of $0.7m was achieved in FY2018 compared to breakeven in FY2017. Underlying NPAT was $0.7m in FY2018 compared to $(1.9)m loss in FY2017.

As at 31 December 2018, EXL has a strong net cash position of $42.7m ($42.9m cash and $0.25m in debt).

Operational update

Key activities by geography during the year:

United States of America

Elixinol

Elixinol reported revenues of $32.5m up 141% on FY2017. Elixinol has continued strong revenue growth across all sales channels which include direct to consumer, wholesale, private label and bulk sales led by broader consumer awareness and demand for hemp-derived CBD products.

In late December 2018, the much awaited 2018 US Farm Bill was signed by the US President, which saw hemp removed from the Controlled Substances Act. This major regulatory change paves the way for significant trade and marketing opportunities for the hemp-derived CBD industry. Research firm, Brightfield Group, revised its forecast for US market growth (September 2018), indicating that the US market size would grow from US$174m in 2016 to US$22bn by 2022 (a significant increase over its 2017 report projection of growth in sales to US$2bn by 2022).

Elixinol's sales initiatives and development activities are focused on penetrating mainstream distribution channels in the US to commence national distribution of its unique, high-quality hemp CBD products; to increase its digital marketing presence to further grow direct to consumer e-commerce sales and continue to advance its technologies to support its existing key private label and bulk sale clients.

Elixinol also initiated technology upgrades to its direct to consumer logistics channel. Further updates to Elixinol's website www.elixinol.com are expected in Q1 FY2019. Furthermore, to help build national brand awareness, leading advertising, public relations and marketing agencies are expected to be appointed in early 2019.

As hemp products have become more accepted by US consumers, Elixinol launched SATIVA Skin Care to US consumers on 8 December 2018. During the year, Elixinol's new product development team advanced its R&D efforts in new technologies and formulations in preparation for new product launches in 2019.

Post the reporting period, Elixinol has launched, via all regular US channels, a new branded product of water soluble, full spectrum, rapidly dissolving CBD powdered drink mixes. 'Create' version intended for the morning, 'Build' for the day, and 'Dream' before bed, designed for daily enjoyment.

Commissioning of Elixinol's Louisville facility is well advanced, following minor construction delays. Final commissioning is expected during H1 FY2019 which will more than double current production capacity. Once commissioned, operations will expand from an 8,700 sq ft facility to 20,700 sq ft, resulting in new production capabilities of 5,000 kg of ethanol extracted hemp CBD extract and 3,125 kg of CO2 extracted hemp CBD extract, with a bottling capacity of 24,000 bottles per day.

Elixinol entered into a farming joint venture, NCHPP in April 2018. The first harvest of high quality CBD hemp occurred in the final quarter of FY2018, with initial yields being lower than expected and anticipated to improve in future crop cycles. Outside of the NCHPP JV, Elixinol has secured the supply of raw material to deliver FY2019 revenues in excess of its current growth trajectory.

Australia

Hemp Foods Australia

Hemp Foods Australia reported revenues of $4.9m(4) up 51% on FY2017. Growth has been supported in regular channels (B2C, B2B, distributor and export) with the addition of Essential Hemp snack bar range.

To support the company's growth initiatives, 2018 saw a significant restructure of the sales and marketing functions to assist with driving into the mass consumer market, and provide improved efficiencies in the distribution of all Hemp Foods Australia's hemp products. Hemp Foods Australia also continues to develop arrangements for local supply of hemp seeds whilst continuing its normal operating activities with existing overseas suppliers.

During FY2018, Hemp Foods Australia invested in the development of new products and new food categories. A number of new product launches took place during the year which included the launch of SATIVA Skin Care to Australian consumers and a range of snack bars under the Essential Hemp(TM) brand. With the frozen and ready meal category forecast to see solid growth, Hemp Foods Australia has also been positioning itself to bring plant based nutritional products to consumers. Our focus into the branded product categories has started successfully in Q1 2019 with our hemp burgers launched into the plant based ready meal category.

(4) Includes $0.3m of intercompany sales of Sativa products (eliminated upon consolidation)

Nunyara Pharma (Medical Cannabis)

In late FY2018, EXL's Australian based medical cannabis company Elixinol Pty Ltd was renamed "Nunyara Pharma Pty Ltd". The name change was designed to clearly differentiate the pharmaceutical grade medical cannabis activities of Nunyara from those of EXL's Colorado-based business, Elixinol, which is focused on hemp-derived CBD dietary supplements and fast moving consumer goods.

Nunyara's licence submissions for the cultivation and manufacturing of medicinal cannabis continue to be under review by the Office of Drug Control (ODC) and we remain optimistic despite the ODC being unable to provide any timing on the granting of both licences.

The Development Application (DA) for the Nunyara's integrated cultivation and manufacture facility is under review. The comprehensive operational plan for the facility is completed and a project manager has been appointed to oversee the construction of the facility. A future focus will be on the construction of the company's state of the art facility.

The unique 60-acre lot is located in the Northern Rivers District of New South Wales, Australia and was purchased on 7 February 2019 for $2.6m. The first stage of the integrated state of the art medical cannabis cultivation and manufacturing facility will be a 5,000m(2) footprint on a secured 4.9-acre lot within the 60 acre property, with significant capacity to expand the proposed greenhouses as required and in-built expansion capacity within the proposed GMP certified, pharmaceutical grade manufacturing facility. Nunyara intends to leverage the significant know-how and experience of Elixinol's Colorado operations.

Rest of World

Set against a favourable macro environment, a number of key initiatives were deployed in FY2018 to drive top line revenue growth across EXL's businesses internationally in FY2019 and beyond. A core focus for Elixinol is growing sales in US, Japan, Europe and more recently New Zealand where Elixinol has recently entered and commenced sales.

In early 2019, a team of highly experienced sales and marketing employees commenced with Elixinol to drive the Group's launch into Europe. Sales hubs have been established in the Netherlands, Spain and United Kingdom and a new e-commerce website was launched Q1 FY2019 to facilitate European sales. Product fulfillment will be supported by local European based contract manufacturers. The European strategy incorporates both a direct sales force and sales via existing distributors. Market research shows that the European cannabis market alone will drive annual sales of EUR115.7bn by 2028 (European Cannabis Report 2018).

In November 2018, the Group's ownership interest in Elixinol Japan was increased to 50.5% (not currently consolidated into our results) via a $2.2m investment to fund working capital. Elixinol's focus in Japan has been on strengthening the management and sales function to support anticipated sales growth of Elixinol's CBD products. Additionally, R&D activities for novel hemp/CBD products specifically catering to the Japanese market are currently being undertaken.

(MORE TO FOLLOW) Dow Jones Newswires

February 27, 2019 12:33 ET (17:33 GMT)

Press Release: Elixinol Global Limited FY2018 -2-

Entry into the New Zealand market followed the passage of New Zealand's Misuse of Drugs (Medicinal Cannabis) Amendment Act in December 2018, which re-classified CBD with low levels of THC as prescription medicine and removes CBD as a Class B1 controlled drug. This change enables patients to import product from Elixinol's CBD range and the first shipment has successfully occurred.

Elixinol continues to explore opportunities throughout Asia and Central and Southern America and will ensure the market is fully informed of any future developments.

Growth Initiatives

Growth Initiatives

EXL is investing in top line revenue growth and production efficiencies across all businesses . This is being led through:

-- Continuing R&D into bio-available and water-soluble bio-technologies

-- Securing supply for growing demand

-- Implementing Enterprise Resource Planning systems

-- Manufacturing capacity

-- Distribution

-- Increased investment into marketing

-- Growing world-class team

-- E-commerce

Outlook

Paul Benhaim, CEO of Elixinol Global, stated, "We are very pleased with our revenue growth of 121% for FY2018 across our businesses globally.

Meetings with large national outlets have indicated that support from the FDA and United Nations will be the next major catalyst for industry growth in both the hemp and cannabis sectors leading to consumer awareness creating demand.

Previous drivers behind these sectors have been supported by several recent positive regulatory changes, including the passage of the US Farm Bill last December, the World Health Organisation's recommendation to the United Nations Committee of Narcotic Drugs to reschedule cannabis, the European Parliament's support and New Zealand's recent move to recognise CBD as a simply prescribed product.

Our robust balance sheet allows the Group to leverage our decades of experience to confidently execute on our strategic growth plans."

Reconciliation to FY2018 underlying EBITDA and NPAT

($m) FY2018

Statutory NPAT (0.9)

Tax expense 0.4

Depreciation & amortisation 0.8

Interest income/finance costs (0.4)

Statutory EBITDA (0.1)

Share based payment expense 0.8

Underlying EBITDA 0.7

Statutory NPAT (0.9)

Share based payment expense (after tax) 0.6

Amortisation acquired intangibles (after tax) 0.3

Tax benefit of losses 0.7

Underlying NPAT 0.7

* FY2017 is shown on a pro forma basis. EXL reports in A$ million and on a 31 December year end.

About Elixinol Global

Elixinol Global Limited (ASX:EXL; OTCQX:ELLXF) through its businesses has a global presence in the cannabis industry including hemp-derived CBD dietary supplements, hemp food and wellness products, as well as cultivation and manufacture of medicinal cannabis products. EXL's businesses include:

-- Elixinol LLC ("Elixinol"), founded in 2014, is a manufacturer and global

distributor of hemp dietary supplement and skincare products, with

operations based out of Colorado, USA.

-- Hemp Foods Australia Pty Ltd ("Hemp Foods Australia"), founded in 1999,

is a leading hemp food wholesaler, retailer, manufacturer and exporter of

bulk and branded raw materials, and finished products.

-- Nunyara Pharma Pty Ltd ("Nunyara"), formerly known as Elixinol Australia,

was founded in 2014 to participate in the emerging Australian medicinal

cannabis market and submitted licence applications for cultivation and

manufacture to the Office of Drug Control in early 2018. These

applications are currently pending approval.

See more at www.elixinolglobal.com

See more at www.elixinolglobal.com

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The ASX has not reviewed, approved or disapproved the content of this press release.

Media Contacts

EXL Global

Cody Slach, Account Director

IR Department Managing Director, Liolios Group Inc

[e-mail]

[phone]

(END) Dow Jones Newswires

February 27, 2019 12:33 ET (17:33 GMT)

[mick]

thank you,$ELLXF

[53man]

Great article thanks for sharing!

[aries4747]

The Power of Investing in Regular Habits

https://investorplace.com/2019/03/the-power-of-investing-in-regular-habits/

Mar 27, 2019, 5:00 pm EDT
The Power of Investing in Regular Habits
Investing using what you already know about consumers
By Luis Hernandez, Managing Editor
http://bit.ly/2CINeAj

It was when I purchased my house that I first heard of “The Starbucks Effect.”

The idea is easy to understand: a Starbucks near your house raises the value of your property. CBS News reported on the results of a Harvard study showing that when a Starbucks is introduced into a zip code, home values nearby increase by 0.5% within a year.

Starbucks isn’t the only one. You can find studies showing similar effects around Trader Joe’s and Whole Foods.

Tracking the correlation can be a bit of a chicken-or-egg question (BTW, the answer is the egg, but that’s another essay). Good retailers spot growing housing markets and open stores nearby.

At the same time, proximity to one of these retailers boosts home selling prices too because people are willing to pay a premium to be near their preferred brands.

And all this illustrates one of our favorite investing themes.

Let me explain….

We’re big believers in investing in products that are habit-forming.

It’s pretty easy to see why when you look at the history of the market.

If you look at the list of the 20 best-performing large U.S. stocks from 1957 through 2003 that kept their general corporate structure intact, you’ll note many of them sold branded consumer products.

Phillip Morris is at the top of the list. It was the top-performing large U.S. stock from 1957 to 2003. It sold cigarettes.

Coca-Cola and Pepsi Co. are on the list. They sold soda. Hershey Foods and Tootsie Roll are on the list. They sold chocolate and sugar.

These businesses produced more than 13% annual gains for decades. You won’t find anything better. Most companies can’t sustain 13% annual returns for more than five years. The businesses mentioned sustained those returns for decades. The reason they did so well is simple…

They sold habit-forming products.

When people form a habit around a product, it goes a long way toward ensuring repeat business. People get used to certain brands and they grow resistant to switching.

That resistance means they will happily continue buying the product even if the price increases a little. Both of these qualities help companies sustain sales growth and healthy profit margins.

For a recent example of this strategy, look to the coffee chain Starbucks. It’s one of the great success stories of American business.

From 1995 to 2006, Starbuck’s market value advanced more than 2,000%. Starbucks was very good at selling high quality coffee with a great brand, and shareholders made a fortune.

But don’t get the idea that the big gains for Starbucks stock are over. Neil George, editor of Profitable Investing, recommended buying Starbucks in early February 2018, and has since seen a lift of 38% in the stock price.

In fact, the coffee maker’s stock hit a new 52-week high yesterday. The chart below reflects the SBUX performance since Neil recommended buying it.

To be sure, SBUX had a tumultuous summer. Concerns over growth in China had a lot of people bailing out. But if you stuck with it, as Neil advised, you’re sitting on a nice profit.

Why is the stock doing so well? Growth and more growth to help people feed their Starbucks coffee habit. Here is Neil’s summary from earlier this year.

While there are nearly 30,000 stores around the world, there are still more coming. About half are owned by the company, with the rest under contract. And while there is arguably a saturation in the US market, in China, where coffee is challenging tea for market share, the company is pushing to get to 6,000 stores over the next four years.

Plus, as more and more folks are spending money on “experiences” rather than items to consume, Starbucks is moving to roll out more of its large roaster stores, which come across as a sort of brewpub for coffee fans, around the world.

And if experience isn’t what customers want, then there’s the speed and convenience through its new push with Uber and Alibaba (BABA) to deliver coffee right to your home or office. In the US alone, the company is geared to have 2,000 of its stores equipped for delivery in short order.

At this new high price, Neil is telling his Profitable Investing subscribers to only buy Starbucks on the dips.

But coffee isn’t even our favorite habit-forming trend for investors.

If you want to understand how to make money from habit-forming trends, make sure and read this recent Forbes story on Daniel Lubetzky, the founder of Kind Health Snacks, maker of the highly popular Kind Bars.

Kind rakes in an estimated $800 million in annual sales. Forbes estimates that the company is worth $2.9 billion, which makes Lubetzky’s share of the company worth over a billion dollars.

Lubetsky has found huge success by selling high-quality, habit-forming consumer goods that have such great brands people are willing to pay up for them.

Just like Starbucks….or Whole Foods….

That strategy is key to understanding the appeal of so many marijuana stocks.

And Matt McCall is putting that strategy into action with his Investment Opportunities service. Matt identified the marijuana trend years ago. Now, he is finding the stocks that are best poised to take advantage of this once-in-a-generation opportunity to build wealth.

Late last year, Matt started his Cannabis Cash Calendar campaign where he picks the new leaders in this global trend – the massively successful private companies that are fueling this surging market and now going public,

Many trade at just pennies a share, or maybe a few dollars. On Dec. 4, Matt made a specific call for one of these companies – Elixinol Global Limited (ELLXF).

Elixinol is widely regarded as one of the most influential CBD brands in the world. The business is divided into three units: dietary supplements, hemp foods, and medicinal cannabis. The first two make consumer products, which have huge upside potential. The third is in the pharmaceuticals sector.

The dietary supplement group is known as Elixinol USA. It generated 84% of the company’s sales in the first half of 2018. It sells 30 different products, from capsules to skin cream to dog treats.

Below is a chart with the stock’s performance since Matt’s call. The stock is up 128%!

Here is Matt’s latest update on the stock from earlier this month.

Elixinol Global Limited (ELLXF) reported strong fiscal 2018 results last week, with total revenue increasing 121% to $26.3 million. Its hemp-CBD business division accounted for $23 million of that, up an impressive 141% over the previous year. That strength is exactly why this stock was our first Cannabis Cash Calendar recommendation.

On top of expanding its brand awareness in the quarter, the company also launched its CBD-based SATIVA skin care line in the United States.

Matt believes Elixinol, and one other stock in his portfolio, have the potential to jump to a major U.S. stock exchange and sign a key deal with a national retailer. I can’t reveal the other stock out of respect for his paid subscribers, but Matt believes both have big long-term potential.

CBD products have amazing potential to be the next big habit-forming consumer trend. One estimate puts the size of the potential market at $22 billion by 2022. As Jeff mentioned Monday, even CVS has stuck a toe in the water by carrying CBD-infused lotions in a limited number of stories. It’s a small start but access to a retailer that size could be a huge catalyst for CBD sales.

And luxury brand Barneys New York recently announced plans to sell CBD-infused products and cannabis accessories in a new “luxury” head shop called The High End.

If you aren’t in the marijuana market yet, there is still time. Matt will reveal his next pick next week. Click here to see how to get that pick on April 4.

Retailers such as Starbucks and Whole Foods could begin to carry CBD-infused products, such as gummies or health bars or drinks, and the trend will only get stronger.

Regardless, investing in habit-forming trends is a winning strategy and we will keep you informed of the next steps in this market.

To a richer life…

Luis Hernandez, Managing Editor
and the research team at InvestorPlace.com

10 STOCKS SET FOR MONSTER GROWTH IN 2019

[aries4747]

ELLXF CEO speaking at Colorado Hemp Conference

https://twitter.com/ElixinolGlobal?ref_src=twsrc%5Etfw%7Ctwcamp%5Eembeddedtimeline%7Ctwterm%5Eprofile%3AElixinolGlobal&ref_url=https%3A%2F%2Fwww.elixinolglobal.com%2Fsite%2Fcontent%2F

https://nocohempexpo.com/

[DilJam]

Nice snag!

[aries4747]

Adds one more positive box checked.

[ANIA77]

Yes, that definitely takes a pressure off the stock chart wise

[aries4747]

Glad to see that gap filled.

[ANIA77]

...and second gap is closed.
I doubt it will go down all the way to MA50 2.48.. .. I think 2.7ish could the bottom if it gets there

[deadjim]

Looks good as any - just loaded 2.96

[RavenStu52]

https://www.marijuanamoment.net/house-will-vote-to-end-federal-marijuana-prohibition-within-weeks-key-chairman-says/

[RavenStu52]

https://insiderfinancial.com/elixinol-global-ltd-otcmktsellxf-signaling-significant-bullish-breakout/178163/

[RavenStu52]

https://www.elixinolglobal.com/site/showdownloaddoc.aspx?AnnounceGuid=1b141f1c-d9c5-4dd6-b4cd-5ae41c6dba43

[CannaBeast]

Walgreens to sell CBD products in 1,500 stores

Walgreens will sell the cannabis-based products in Oregon, Colorado, New Mexico, Kentucky, Tennessee, Vermont, South Carolina, Illinois and Indiana.

Rival drugstore chain CVS introduced CBD-containing topicals, including creams and salves, to stores in eight states earlier in March.

https://www.cnbc.com/amp/2019/03/27/walgreens-to-sell-cbd-products-in-some-stores.html?__twitter_impression=true

[RavenStu52]

Sweet comeback on big volume. Banking bill vote close

[deadjim]

If this was the low then what a strong sob. But hey I always appreciate someone who can look at both fundamentals and apply TA. Seems like you always get one extreme or the other around these boards (ta vs fundies, rather than both)

[deadjim]

Guess we’ll see tomorrow. That might’ve been it though. will probably take a few days to tell

[ANIA77]

2.9-3.0 closes gap and it gives you 50% retracement from last leg.
2.5 range would be more than 62% Fibonacci retracement.. I would doubt it would get there... however MA50 is only 2.46 currently.. let's see what happens.

[ANIA77]

First gap just closed. I think second gap is all the way down to 3.0

[RavenStu52]

Where are you charting the gaps at

[deadjim]

$3 bucks?-2-50 range.. somewhere in there

[deadjim]

Yeah it might. I’d prefer it dips just high enough that it’s too high for people to jump in, then turns and leaves them behind.. as any bullish stock tends to do. But I’ll just keep an eye.. good buy Opp coming either way

[ANIA77]

....and here's the pullback.. I would like those gaps to be closed on a chart.. before another move higher

[deadjim]

Yep, wild this is holding up with the sector down. I’m overloaded so I took a few off Incase it’s just trailing others

[ANIA77]

There are two gaps in a chart so I think pullback is in cards here.. surprised seeing it still staying in accumulation mode..
It must be still under radar and not attractive for daytraders.

[RavenStu52]

The only thing Green on my board

[ANIA77]

Pullback day everywhere except here..

[DilJam]

The 60.. the 30.. the daily.. it's all bullish lol. It very well could run further but it's all about risk management and better to sell into strength before the bids dry out. Especially on a low-volume play like this one.

[deadjim]

60 min's super bullish

[DilJam]

I agree. Took some off the table today as well. She should be coming back down soon and with the relatively low volume here, it may happen quickly.

[CannaBeast]

Yeah, it’s really hard to tell with a gem like $ELLXF, but based solely on TA, you’re right

This is the #2 CBD stock to own, and we haven’t had earnings nor any major news announcement — which can occur at any time

I’ve decided to keep a very nice core position, and will add on dips. Ever since the CVS news — carrying CBD products, you know it’s just weeks away before we start hearing other major chain retailer announcements

The CBD sector has finally opened its eyes; we are still very early

[ShtockMahket]

Already doubled my investment from December, looking good. Did a little bit of profit-taking because I think we're a bit too overbought now and I don't think there's enough news to back it up. We'll see, though.

[deadjim]

Im loving this.. just incremental moves. The real chasing has begun.

[aries4747]

A 23,800 buy at 3.44 (above the Ask) went through a couple of minutes after open.

[starkd748]

Baaaboooom

[ANIA77]

Looks like another new 52wk high day coming.. very strong open

[Pan_O_War]

I bought in today. Happy to be LONG here.

[FastMny]

This is a rock solid play.

[CannaBeast]

Very nice, same here

[starkd748]

My #2 also then i got a couple otc spec plays....

[Ihal]

Beast

[CannaBeast]

She’s pretty, she’s my #2

[starkd748]

She's pretty

[deadjim]

What a beauty

[aries4747]

Will Pot Stocks Live Up To Their Promise?

http://www.thebull.com.au/premium/a/80922-will-pot-stocks-live-up-to-their-promise.html

[starkd748]

Yea see that 20$ on the other one

[deadjim]

Blink and she’ll be 4. Stepping stone to pop